Back to top

Tale of the Tape

Mindray Medical International Ltd’s (MR - Analyst Report) share price has entered into oversold territory with an RSI value of 28.7. The Zacks Consensus Estimate for Mindray for the full year period has improved 2 cents over the past two months to $2.14 per share. Currently, Mindray has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on (MR - Analyst Report) after its recent drop.

Please login to Zacks.com or register to post a comment.